These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24529482)

  • 1. Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer?
    Tessier W; Gronnier C; Messager M; Hec F; Mirabel X; Robb WB; Piessen G; Mariette C
    Ann Thorac Surg; 2014 Apr; 97(4):1181-9. PubMed ID: 24529482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis.
    Qin Q; Xu H; Liu J; Zhang C; Xu L; Di X; Zhang X; Sun X
    Int J Surg; 2018 Nov; 59():11-18. PubMed ID: 30261331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
    Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
    Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of minimally invasive esophagectomy in esophageal cancer after neoadjuvant chemoradiotherapy.
    Warner S; Chang YH; Paripati H; Ross H; Ashman J; Harold K; Day R; Stucky CC; Rule W; Jaroszewski D
    Ann Thorac Surg; 2014 Feb; 97(2):439-45. PubMed ID: 24266955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing?
    Ranney DN; Mulvihill MS; Yerokun BA; Fitch Z; Sun Z; Yang CF; D'Amico TA; Hartwig MG
    Eur J Cardiothorac Surg; 2017 Sep; 52(3):543-551. PubMed ID: 28498967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
    Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
    Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma.
    Kathiravetpillai N; Koëter M; van der Sangen MJ; Creemers GJ; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Aug; 42(8):1183-90. PubMed ID: 27134188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
    Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
    Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Interval Between Neoadjuvant Chemoradiation and Surgery Upon Morbidity and Survival of Patients with Squamous Cell Carcinoma of Thoracic Esophagus.
    Furukawa T; Hamai Y; Hihara J; Emi M; Yamakita I; Ibuki Y; Kurokawa T; Okada M
    Anticancer Res; 2018 Sep; 38(9):5239-5245. PubMed ID: 30194173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
    Lin G; Han SY; Xu YP; Mao WM
    Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of patient selection, disease progression, and adverse events on esophageal cancer outcomes after trimodality therapy.
    Gilbert S; Gresham GK; Jonker DJ; Seely AJ; Maziak DE; Shamji FM; Pantarotto J; Sundaresan S
    Ann Thorac Surg; 2012 Nov; 94(5):1659-66. PubMed ID: 22981444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
    Chao YK; Tseng CK; Wen YW; Liu YH; Wan YL; Chiu CT; Chang WC; Chang HK
    Ann Surg Oncol; 2013 Sep; 20(9):3000-8. PubMed ID: 23584515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
    Mariette C; Taillier G; Van Seuningen I; Triboulet JP
    Ann Thorac Surg; 2004 Oct; 78(4):1177-83. PubMed ID: 15464466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns.
    Koshy M; Greenwald BD; Hausner P; Krasna MJ; Horiba N; Battafarano RJ; Burrows W; Suntharalingam M
    Am J Clin Oncol; 2011 Jun; 34(3):259-64. PubMed ID: 20686405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of neoadjuvant chemoradiotherapy on postoperative outcomes after esophageal cancer resection: results of a European multicenter study.
    Gronnier C; Tréchot B; Duhamel A; Mabrut JY; Bail JP; Carrere N; Lefevre JH; Brigand C; Vaillant JC; Adham M; Msika S; Demartines N; El Nakadi I; Piessen G; Meunier B; Collet D; Mariette C; ; Luc G; Cabau M; Jougon J; Badic B; Lozach P; Cappeliez S; Lebreton G; Alves A; Flamein R; Pezet D; Pipitone F; Iuga BS; Contival N; Pappalardo E; Mantziari S; Hec F; Vanderbeken M; Tessier W; Briez N; Fredon F; Gainant A; Mathonnet M; Bigourdan JM; Mezoughi S; Ducerf C; Baulieux J; Pasquer A; Baraket O; Poncet G; Vaudoyer D; Enfer J; Villeneuve L; Glehen O; Coste T; Fabre JM; Marchal F; Frisoni R; Ayav A; Brunaud L; Bresler L; Cohen C; Aze O; Venissac N; Pop D; Mouroux J; Donici I; Prudhomme M; Felli E; Lisunfui S; Seman M; Petit GG; Karoui M; Tresallet C; Ménégaux F; Hannoun L; Malgras B; Lantuas D; Pautrat K; Pocard M; Valleur P
    Ann Surg; 2014 Nov; 260(5):764-70; discussion 770-1. PubMed ID: 25379847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-expanding covered metallic stent as a bridge to surgery in esophageal cancer: impact on oncologic outcomes.
    Mariette C; Gronnier C; Duhamel A; Mabrut JY; Bail JP; Carrere N; Lefevre JH; Meunier B; Collet D; Piessen G; ;
    J Am Coll Surg; 2015 Mar; 220(3):287-96. PubMed ID: 25617915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma.
    Marks JL; Hofstetter W; Correa AM; Mehran RJ; Rice D; Roth J; Walsh G; Vaporciyan A; Erasmus J; Chang J; Maru D; Lee JH; Lee J; Ajani JA; Swisher SG
    Ann Thorac Surg; 2012 Oct; 94(4):1126-32; discussion 1132-3. PubMed ID: 22921233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.